SCHEMBL6090662

SCHEMBL6090662

CN(C)c1ccc(C(=O)C=CC23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
RAB9A P51151 6/20 0.48
NPC1 O15118 5/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
KMT2A Q03164 4/20 0.48
CASP3 P42574 1/20 0.48
CYP1B1 Q16678 1/20 0.48
SENP8 Q96LD8 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
SENP6 Q9GZR1 1/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
TLR9 Q9NR96 1/20 0.47
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 3/20 0.44
HPGD P15428 2/20 0.44
MAOB P27338 2/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18317449 0.81 RAB9A (0.45) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL6092092 0.81 TNFRSF1A (0.47) MAPTRAB9ANPC1SMN1; SMN2CYP1B1
SCHEMBL6090897 0.81 P2RX7 (0.46) MAPTRAB9ANPC1CYP1B1KDM4E
SCHEMBL6091141 0.80 FAAH (0.49) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL6093635 0.80 CNR2 (0.55) MAPTRAB9ANPC1KMT2ACYP1B1
SCHEMBL6093038 0.80 HDAC1 (0.41) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL6093069 0.80 ALDH1A1 (0.43) MAPTRAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL6092329 0.78 KMT2A (0.48) SMN1; SMN2KMT2AKDM4EALDH1A1LMNA
SCHEMBL3431570 0.72 GPR52 (0.42) MAPTKMT2AKDM4EALDH1A1HPGD
SCHEMBL4729406 0.72 PKM (0.46) MAPTRAB9ANPC1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US claimed
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders MERZ PHARMA GMBH & CO. KGAA (DE) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074083-A1 Cyclic and acyclic propenones for treating CNS disorders PMP22, ADCYAP1R1, CYP11B2 MAPT 87/4885RAB9A 3821/4885NPC1 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.